A meta-analysis of clinical genomics data showed that overexpression of GALNT14 or HOXB9 was strongly correlated with reduced RFS and increased HR, suggesting that targeting the GALNT14/WNT/HOXB9 axis might be a novel therapeutic approach to inhibit NSCLC metastasis. The gene discussed is HOXB9; the disease is non-small cell lung carcinoma.